Recent studies utilizing BRAF and MEK inhibitors (e.g. vermurafenib, dabrafenib, trametinib) have shown efficacy in treating ECD with limited toxicity [29, 30, 33, 34]. This evidence concerns the gene MAP2K7 and familial atrioventricular septal defect.